1
Head & Neck Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Head & Neck Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511
Aarti Bhatia, MD, MPH
Medical Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine, Medical Oncology
, and Hematology (Internal Medicine)
Titles
- Associate Professor of Medicine (Medical Oncology)
- Clinical Research Team Leader, Head and Neck Cancers Program
Education & Training
- FellowshipTemple University/Fox Chase Cancer Center (2015)
- ResidencyJohns Hopkins University/Sinai Hospital (2012)
- MPHUniversity of Texas School of Public Health (2011)
- MDTN Medical School (2007)
Additional Information
Publications
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung C. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. Journal Of Clinical Oncology 2023, 41: 3851-3862. PMID: 36977289, DOI: 10.1200/jco.22.01994.
- Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.
- Bhatia A. Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. The Cancer Journal 2022, 28: 331-338. PMID: 36165720, DOI: 10.1097/ppo.0000000000000623.
- Bhatia A, Chen Z, Bruce J, Steuer C, Zandberg D, Riess J, Mitchell D, Davis T, Patel M, Kaur V, Arnold S, Owonikoko T. 656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma. Annals Of Oncology 2022, 33: s842. DOI: 10.1016/j.annonc.2022.07.780.
- Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtness B. A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202. Journal Of Clinical Oncology 2022, 40: tps6098-tps6098. DOI: 10.1200/jco.2022.40.16_suppl.tps6098.
- Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, Tse B, Pointdujour-Lim R. Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases. Ophthalmic Plastic And Reconstructive Surgery 2022, 38: 496-502. PMID: 35502804, DOI: 10.1097/iop.0000000000002190.
- Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.
- Siegel JD, Bhatia A, Ko CJ, Christensen SR. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab. JAAD Case Reports 2021, 18: 23-25. PMID: 34778502, PMCID: PMC8577130, DOI: 10.1016/j.jdcr.2021.10.009.
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Saboda K, Obara S, Chung C. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6015-6015. DOI: 10.1200/jco.2021.39.15_suppl.6015.
- Forman R, Bhatia A, Burtness B. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. Journal Of Clinical Oncology 2021, 39: 6042-6042. DOI: 10.1200/jco.2021.39.15_suppl.6042.
- Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research 2021, 10: 2571-2585. PMID: 35116571, PMCID: PMC8798834, DOI: 10.21037/tcr-20-2096.
- Bauman J, Roe D, Saba N, Bauman J, Kaczmar J, Burtness B, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Bhatia A, Giri A, Caulin C, Stabile L, Centuori S, Chung C. Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: tps6594-tps6594. DOI: 10.1200/jco.2020.38.15_suppl.tps6594.
- Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancerSaeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.
- Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant TherapyLOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.
- Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant TherapyLoganadane G, Kann B, Park H, Johnson S, Mehra S, Judson B, Bhatia A, Belkacemi Y, Yarbrough W, Burtness B, Husain Z. Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant Therapy. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e375-e376. DOI: 10.1016/j.ijrobp.2019.06.1628.
- Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, Park HS, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma. The Laryngoscope 2018, 129: 883-889. PMID: 30151947, DOI: 10.1002/lary.27444.
- Peri S, Andrews A, Bhatia A, Mehra R. Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer. 2018, 327-352. DOI: 10.1007/978-3-319-78762-6_12.
- Doroshow D, Deshpande H, Remick S, Bhatia A. Hypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma. Journal Of Clinical Oncology 2018, 36: e18108-e18108. DOI: 10.1200/jco.2018.36.15_suppl.e18108.
- Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.
- Bhatia AK, Burtness BA, Decker RH. Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2018, 36: jco.2018.77.798. PMID: 29547345, DOI: 10.1200/jco.2018.77.7987.
- Cheraghlou S, Yu PK, Otremba MD, Park HS, Bhatia A, Zogg CK, Mehra S, Yarbrough WG, Judson BL. Treatment deintensification in human papillomavirus‐positive oropharynx cancer: Outcomes from the National Cancer Data Base. Cancer 2017, 124: 717-726. PMID: 29243245, DOI: 10.1002/cncr.31104.
- Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.
- Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9: 113. PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.
- Bhatia AK, Lee J, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez‐Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590). Cancer 2017, 123: 4653-4662. PMID: 28786105, PMCID: PMC5693641, DOI: 10.1002/cncr.30920.
- Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.
- Bhatia A, Lee J, Pinto H, Jacobs C, Limburg P, Arusell R, Dunphy E, Khandekar J, Reiner S, Baez-Diaz L, Celano P, Li S, Li Y, Burtness B, Pandya K. Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590). Journal Of Clinical Oncology 2016, 34: 1507-1507. DOI: 10.1200/jco.2016.34.15_suppl.1507.
- Bhatia A, Mehra R, Khan S, Egleston B, Alpaugh R, Lango M, Ridge J, Burtness B. Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2016, 34: 6027-6027. DOI: 10.1200/jco.2016.34.15_suppl.6027.
- Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.
- Vijayvergia N, Innocent J, Bhatia A, Shameem R, Xiu J, Gatalica Z, Grivennikov S, El-Deiry W. Reduced PD-1/PD-L1 expression in KRAS-mutant versus wild-type microsatellite instable (MSI-H) colorectal cancer (CRC) and association of wnt pathway corepressor TLE-3. Journal Of Clinical Oncology 2015, 33: 3611-3611. DOI: 10.1200/jco.2015.33.15_suppl.3611.
- Shagisultanova E, Vijayvergia N, Shameem R, Bhatia A, Xiu J, Gatalica Z, El-Deiry W. Association of increase in BRCA2 gene mutations in microsatellite instable (MSI-H) colorectal ancer (CRC) with increased c-MET expression. Journal Of Clinical Oncology 2015, 33: e14684-e14684. DOI: 10.1200/jco.2015.33.15_suppl.e14684.
- Girotra M, Bhatia A. Cardiogenic dysphagia: an unusual case. Saudi Journal Of Gastroenterology : Official Journal Of The Saudi Gastroenterology Association 2012, 18: 73. PMID: 22249099, PMCID: PMC3271701, DOI: 10.4103/1319-3767.91725.
- Bhatia A, Rao A, Ang K, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head & Neck 2010, 32: 829-836. PMID: 19885924, DOI: 10.1002/hed.21257.
Departments and Programs
Locations
1
Head & Neck Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Head & Neck Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511
Titles
- Associate Professor of Medicine (Medical Oncology)
- Clinical Research Team Leader, Head and Neck Cancers Program
Education & Training
- FellowshipTemple University/Fox Chase Cancer Center (2015)
- ResidencyJohns Hopkins University/Sinai Hospital (2012)
- MPHUniversity of Texas School of Public Health (2011)
- MDTN Medical School (2007)
Additional Information
Publications
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung C. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. Journal Of Clinical Oncology 2023, 41: 3851-3862. PMID: 36977289, DOI: 10.1200/jco.22.01994.
- Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.
- Bhatia A. Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. The Cancer Journal 2022, 28: 331-338. PMID: 36165720, DOI: 10.1097/ppo.0000000000000623.
- Bhatia A, Chen Z, Bruce J, Steuer C, Zandberg D, Riess J, Mitchell D, Davis T, Patel M, Kaur V, Arnold S, Owonikoko T. 656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma. Annals Of Oncology 2022, 33: s842. DOI: 10.1016/j.annonc.2022.07.780.
- Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtness B. A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202. Journal Of Clinical Oncology 2022, 40: tps6098-tps6098. DOI: 10.1200/jco.2022.40.16_suppl.tps6098.
- Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, Tse B, Pointdujour-Lim R. Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases. Ophthalmic Plastic And Reconstructive Surgery 2022, 38: 496-502. PMID: 35502804, DOI: 10.1097/iop.0000000000002190.
- Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022, 44: 1777-1786. PMID: 35488876, DOI: 10.1002/hed.27077.
- Siegel JD, Bhatia A, Ko CJ, Christensen SR. Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab. JAAD Case Reports 2021, 18: 23-25. PMID: 34778502, PMCID: PMC8577130, DOI: 10.1016/j.jdcr.2021.10.009.
- Bauman J, Saba N, Roe D, Bauman J, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Saboda K, Obara S, Chung C. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6015-6015. DOI: 10.1200/jco.2021.39.15_suppl.6015.
- Forman R, Bhatia A, Burtness B. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients. Journal Of Clinical Oncology 2021, 39: 6042-6042. DOI: 10.1200/jco.2021.39.15_suppl.6042.
- Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review. Translational Cancer Research 2021, 10: 2571-2585. PMID: 35116571, PMCID: PMC8798834, DOI: 10.21037/tcr-20-2096.
- Bauman J, Roe D, Saba N, Bauman J, Kaczmar J, Burtness B, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Bhatia A, Giri A, Caulin C, Stabile L, Centuori S, Chung C. Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: tps6594-tps6594. DOI: 10.1200/jco.2020.38.15_suppl.tps6594.
- Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancerSaeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.
- Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant TherapyLOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.
- Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant TherapyLoganadane G, Kann B, Park H, Johnson S, Mehra S, Judson B, Bhatia A, Belkacemi Y, Yarbrough W, Burtness B, Husain Z. Clinical Outcomes of Head and Neck Cancer Patients who Undergo Resection, but Forgo Adjuvant Therapy. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e375-e376. DOI: 10.1016/j.ijrobp.2019.06.1628.
- Cheraghlou S, Schettino A, Zogg CK, Otremba MD, Bhatia A, Park HS, Osborn HA, Mehra S, Yarbrough WG, Judson BL. Adjuvant Chemotherapy Is Associated With Improved Survival for Late‐Stage Salivary Squamous Cell Carcinoma. The Laryngoscope 2018, 129: 883-889. PMID: 30151947, DOI: 10.1002/lary.27444.
- Peri S, Andrews A, Bhatia A, Mehra R. Epigenetic Changes and Epigenetic Targets in Head and Neck Cancer. 2018, 327-352. DOI: 10.1007/978-3-319-78762-6_12.
- Doroshow D, Deshpande H, Remick S, Bhatia A. Hypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma. Journal Of Clinical Oncology 2018, 36: e18108-e18108. DOI: 10.1200/jco.2018.36.15_suppl.e18108.
- Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.
- Bhatia AK, Burtness BA, Decker RH. Postoperative Chemoradiation in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2018, 36: jco.2018.77.798. PMID: 29547345, DOI: 10.1200/jco.2018.77.7987.
- Cheraghlou S, Yu PK, Otremba MD, Park HS, Bhatia A, Zogg CK, Mehra S, Yarbrough WG, Judson BL. Treatment deintensification in human papillomavirus‐positive oropharynx cancer: Outcomes from the National Cancer Data Base. Cancer 2017, 124: 717-726. PMID: 29243245, DOI: 10.1002/cncr.31104.
- Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.
- Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9: 113. PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.
- Bhatia AK, Lee J, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez‐Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590). Cancer 2017, 123: 4653-4662. PMID: 28786105, PMCID: PMC5693641, DOI: 10.1002/cncr.30920.
- Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.
- Bhatia A, Lee J, Pinto H, Jacobs C, Limburg P, Arusell R, Dunphy E, Khandekar J, Reiner S, Baez-Diaz L, Celano P, Li S, Li Y, Burtness B, Pandya K. Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590). Journal Of Clinical Oncology 2016, 34: 1507-1507. DOI: 10.1200/jco.2016.34.15_suppl.1507.
- Bhatia A, Mehra R, Khan S, Egleston B, Alpaugh R, Lango M, Ridge J, Burtness B. Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2016, 34: 6027-6027. DOI: 10.1200/jco.2016.34.15_suppl.6027.
- Bhatia A, Burtness B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. Journal Of Clinical Oncology 2015, 33: 3243-3250. PMID: 26351343, PMCID: PMC5814107, DOI: 10.1200/jco.2015.61.2358.
- Vijayvergia N, Innocent J, Bhatia A, Shameem R, Xiu J, Gatalica Z, Grivennikov S, El-Deiry W. Reduced PD-1/PD-L1 expression in KRAS-mutant versus wild-type microsatellite instable (MSI-H) colorectal cancer (CRC) and association of wnt pathway corepressor TLE-3. Journal Of Clinical Oncology 2015, 33: 3611-3611. DOI: 10.1200/jco.2015.33.15_suppl.3611.
- Shagisultanova E, Vijayvergia N, Shameem R, Bhatia A, Xiu J, Gatalica Z, El-Deiry W. Association of increase in BRCA2 gene mutations in microsatellite instable (MSI-H) colorectal ancer (CRC) with increased c-MET expression. Journal Of Clinical Oncology 2015, 33: e14684-e14684. DOI: 10.1200/jco.2015.33.15_suppl.e14684.
- Girotra M, Bhatia A. Cardiogenic dysphagia: an unusual case. Saudi Journal Of Gastroenterology : Official Journal Of The Saudi Gastroenterology Association 2012, 18: 73. PMID: 22249099, PMCID: PMC3271701, DOI: 10.4103/1319-3767.91725.
- Bhatia A, Rao A, Ang K, Garden AS, Morrison WH, Rosenthal DI, Evans DB, Clayman G, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. Head & Neck 2010, 32: 829-836. PMID: 19885924, DOI: 10.1002/hed.21257.
Departments and Programs
Locations
1
Head & Neck Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Head & Neck Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511
1
Head & Neck Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 4
New Haven, CT 06511
1 of 2
- Head & Neck Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 4New Haven, CT 06511
- Smilow Cancer Hospital Head and Neck Cancers Program55 Park StreetSte Phase I Clinical Trial Infusion CenterNew Haven, CT 06511